Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
RMPs to Become Statutory Requirement under PMD Act in May 2027
Japan’s health ministry on September 30 issued a series of notifications ahead of the May 20, 2027 enforcement of provisions on risk management plans (RMPs) under the revised Pharmaceuticals and Medical Devices (PMD) Act. Until now, drug makers have been…
To read the full story
Related Article
- Japan’s Parliament Enacts Bill to Amend PMD Act
May 15, 2025
- Quality Assurance and Lag/Loss Fight to Form Pillars of PMD Act Amendment
December 27, 2024
REGULATORY
- Japan Has Limited Drug Pricing Cards to Play on MFN, Should Expand CEA: MOF Official
October 5, 2026
- RMPs to Become Statutory Requirement under PMD Act in May 2027
October 5, 2026
- Japan Panel Calls for Better Infrastructure to Expand RLT Access
October 5, 2026
- Drug Discovery Fund Cleared to Provide Funding to Startups
October 5, 2026
- MHLW Simplifies Repatha Optimal Use Guidelines
October 5, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…